TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky OctoberPfizer (PFE) sued Metsera (MTSR) and Novo Nordisk (NVO) on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused biotech company.The move is the second jab in an escalating battle pitting Pfizer and Novo Nordisk. The first came Thursday when Novo issued an unsolicited bid to buy Metsera, a month after Pfizer struck a deal to acquire Metsera for $4.9 billion.Pfizer's lawsuit asserts that Metsera breached ...

法律诉讼与收购要约 - 辉瑞对Metsera和诺和诺德提起诉讼 指控Metsera在宣布诺和诺德的85亿美元收购要约为更优方案时违反了合并协议义务[1] - 辉瑞请求法院发布临时限制令 以阻止Metsera终止协议[1] - 辉瑞指控诺和诺德的收购要约是市场主导公司的非法尝试 旨在规避反垄断审查并存在重大监管风险[2] - Metsera给予辉瑞提高报价的最后期限为周二[2] 收购进展与反垄断审查 - 辉瑞拟以73亿美元收购Metsera的交易已获得美国联邦贸易委员会的早期反垄断批准[3] - 反垄断审查等待期根据《哈特-斯科特-罗迪诺反托拉斯改进法》提前终止 比11月7日的最后期限提前了一周多[3] 公司战略与市场背景 - 辉瑞目前不销售减肥药 正试图进入快速增长的肥胖症市场 该市场预计到2030年代初将达到1500亿美元[3] - 公司在开发自有疗法方面遭遇挫折 并寻求抵消COVID相关收入下降和即将到来的专利到期影响[4] - 诺和诺德寻求收复被礼来公司抢占的市场份额 礼来的Zepbound和Mounjaro显示出更强的临床效果[4] - Metsera的研发管线包括实验性GLP-1和胰淀素疗法 分析师认为其峰值销售额可能达到50亿美元[4]

(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer. Metsera has declared Novo's offer superior, and given Pfizer until Tuesday to raise its bid. The U.S. Federal Trade Commission granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews. The waiting period was originally set to e ...

法律行动 - 辉瑞公司于周五对Metsera和诺和诺德提起诉讼 [1] - 诉讼指控上述两家公司违反合并协议并干扰交易 [1]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera. Pfizer alleges that the Novo Nordisk offer cannot qualify as a "Superior Company Proposal†u. ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. (NASDAQ:MTSR) jumped to a new 52-week high of $66.10 before trimming gains to end the day just up by 22.06 percent at $63.73 apiece. This fo ...

中新网上海10月31日电 (记者 陈静)过去数年来，中国国际进口博览会见证了中国医疗创新生态的蓬勃 活力。第八届进博会即将开幕。爱德华生命科学(简称：爱德华)日本及亚太地区全球副总裁韦恩·马科维 茨( Wayne Markowitz)31日对记者表示，进博会是全球创新成果进入中国市场的重要平台，更是爱德华 深化本土布局、携手共赢的核心纽带。借助进博会这一国家级开放平台，爱德华将引入更多全球前沿创 新成果，并推动其向临床价值的加速转化，让更多患者从中受益。 在本届进博会上，诺和诺德打造了首个聚焦肥胖症健康管理的沉浸式体验空间——"轻盈小屋"。体验者 可通过AI视觉识别互动技术在屏幕中看见"变胖的自己"，结合相应的科普知识及健康风险提示，唤醒公 众对肥胖症的重视；"科学治疗"部分包括医院与零售两大场景，旨在展示"院店协同"新模式，助力打通 肥胖症院内外管理闭环，提升肥胖症管理的便利性、科学性与依从性。 本届进博会上，"司美格鲁肽家族"多款明星产品将携新进展亮相。诺和盈®(全球首个用于长期体重管理 的GLP-1RA周制剂)中国说明书纳入心血管获益结果；诺和泰®(司美格鲁肽注射液)获批新增慢性肾脏病 (CKD)适应证 ...

礼来公司业绩表现 - 第三季度净收入同比增长近六倍，达到56亿美元，去年同期为9.7亿美元 [2] - 第三季度收入增长54%，达到176亿美元，超出市场预期 [2] - 公司预计今年调整后每股收益为23至23.70美元，高于此前预期的21.75至23美元 [6] - 公司股票在业绩公布后上涨3.8%，2025年迄今累计上涨9.4% [3] GLP-1药物市场表现 - 糖尿病药物Mounjaro第三季度销售额达到65亿美元，同比增长109%，远超华尔街预期的55亿美元 [3] - 减肥药物Zepbound第三季度销售额增长185%，达到36亿美元，超出市场预期 [3] - 公司在包含GLP-1类药物在内的市场份额扩大0.9个百分点至57.9%，诺和诺德以41.7%的份额位居第二 [3] 诺和诺德应对策略 - 诺和诺德提出以90亿美元收购纽约肥胖生物技术公司Metsera，超过了辉瑞73亿美元的出价 [4] - 在礼来公布业绩后，诺和诺德股价下跌2.6%，今年迄今累计下跌41.6% [3] - 诺和诺德曾被模仿药物制造商困扰，并在战略上出现失误 [3]

公司运营调整 - 诺和诺德已通知在绝大多数地点受裁员影响的员工 [1] - 裁员通知的进度因当地法律不同而异 [1]

并购竞争态势 - 诺和诺德对肥胖症生物技术公司Metsera提出意外竞购 [1] - 辉瑞可能利用其与特朗普政府的关系试图阻挠诺和诺德的竞购 [1] 公司战略动向 - 辉瑞被提及为潜在的交易参与者 [1] - 并购目标Metsera是一家专注于肥胖症领域的美国生物技术公司 [1]